{"transactions":[{"id":686982,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"officer":true,"officer_title":"EVP, Head of North America"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-08-14T23:04:44.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":false,"shares":21601,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":0,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":21601},"source":{"system":"sec-edgar","filing":"0001649904-26-000009","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000164990426000009/form4.xml","form_type":"4"}},{"id":686981,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"officer":true,"officer_title":"EVP, Head of North America"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-08-14T23:04:44.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter."}],"balance_after":36283,"derivative":{"exercise_price":24.29,"expiration_date":"2030-11-09","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001649904-26-000009","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000164990426000009/form4.xml","form_type":"4"}},{"id":686980,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"officer":true,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2026-08-14T23:04:44.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":75834,"price":117.3818,"value":8901531.4212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001649904-26-000009","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000164990426000009/form4.xml","form_type":"4"}},{"id":686979,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"officer":true,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2026-08-14T23:04:44.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":true,"shares":21601,"price":6.8,"value":146886.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."}],"balance_after":75834,"source":{"system":"sec-edgar","filing":"0001649904-26-000009","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000164990426000009/form4.xml","form_type":"4"}},{"id":686978,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"officer":true,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2026-08-14T23:04:44.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":24.29,"value":850150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026."}],"balance_after":54233,"source":{"system":"sec-edgar","filing":"0001649904-26-000009","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000164990426000009/form4.xml","form_type":"4"}},{"id":905319,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-02-13T22:49:52.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":32500,"derivative":{"exercise_price":98.47,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001104659-26-015399","document":"tm266366-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926015399/tm266366-4_4seq1.xml","form_type":"4"}},{"id":905318,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T22:49:52.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":21650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date."}],"balance_after":21650,"derivative":{"underlying":"Common Stock","underlying_shares":21650},"source":{"system":"sec-edgar","filing":"0001104659-26-015399","document":"tm266366-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926015399/tm266366-4_4seq1.xml","form_type":"4"}},{"id":922025,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:33:18.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":9163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date."}],"balance_after":27487,"derivative":{"underlying":"Common Stock","underlying_shares":9163},"source":{"system":"sec-edgar","filing":"0001104659-26-009767","document":"tm264963-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926009767/tm264963-4_4seq1.xml","form_type":"4"}},{"id":922024,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:33:18.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date."}],"balance_after":11000,"derivative":{"underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-26-009767","document":"tm264963-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926009767/tm264963-4_4seq1.xml","form_type":"4"}},{"id":922023,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:33:18.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":4512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":4512,"derivative":{"underlying":"Common Stock","underlying_shares":4512},"source":{"system":"sec-edgar","filing":"0001104659-26-009767","document":"tm264963-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926009767/tm264963-4_4seq1.xml","form_type":"4"}},{"id":922022,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:33:18.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":3437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3437},"source":{"system":"sec-edgar","filing":"0001104659-26-009767","document":"tm264963-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926009767/tm264963-4_4seq1.xml","form_type":"4"}},{"id":922021,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2026-02-03T21:33:18.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":9237,"price":108.99,"value":1006740.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein."}],"balance_after":19233,"source":{"system":"sec-edgar","filing":"0001104659-26-009767","document":"tm264963-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926009767/tm264963-4_4seq1.xml","form_type":"4"}},{"id":922020,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2026-02-03T21:33:18.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":22612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":28470,"source":{"system":"sec-edgar","filing":"0001104659-26-009767","document":"tm264963-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465926009767/tm264963-4_4seq1.xml","form_type":"4"}},{"id":1260246,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T02:46:08.000Z","date":"2025-02-16","kind":"exercise","planned":true,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."}],"balance_after":16500,"derivative":{"underlying":"Common Stock","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0001104659-25-015320","document":"tm257103-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925015320/tm257103-4_4seq1.xml","form_type":"4"}},{"id":1260245,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-20T02:46:08.000Z","date":"2025-02-14","kind":"grant","planned":true,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":55000,"derivative":{"exercise_price":56.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-25-015320","document":"tm257103-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925015320/tm257103-4_4seq1.xml","form_type":"4"}},{"id":1260244,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T02:46:08.000Z","date":"2025-02-14","kind":"grant","planned":true,"acquired":true,"shares":36650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date."}],"balance_after":36650,"derivative":{"underlying":"Common Stock","underlying_shares":36650},"source":{"system":"sec-edgar","filing":"0001104659-25-015320","document":"tm257103-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925015320/tm257103-4_4seq1.xml","form_type":"4"}},{"id":1260243,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-20T02:46:08.000Z","date":"2025-02-19","kind":"sale","planned":true,"acquired":false,"shares":2035,"price":57.22,"value":116442.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":5858,"source":{"system":"sec-edgar","filing":"0001104659-25-015320","document":"tm257103-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925015320/tm257103-4_4seq1.xml","form_type":"4"}},{"id":1260242,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-20T02:46:08.000Z","date":"2025-02-16","kind":"exercise","planned":true,"acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7893,"source":{"system":"sec-edgar","filing":"0001104659-25-015320","document":"tm257103-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925015320/tm257103-4_4seq1.xml","form_type":"4"}},{"id":1267470,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-14T21:55:57.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":1205,"price":58,"value":69890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."}],"balance_after":2393,"source":{"system":"sec-edgar","filing":"0001104659-25-014257","document":"tm256729-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925014257/tm256729-1_4seq1.xml","form_type":"4"}},{"id":1267469,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-14T21:55:57.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":1205,"price":56.39,"value":67949.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."}],"balance_after":3598,"source":{"system":"sec-edgar","filing":"0001104659-25-014257","document":"tm256729-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925014257/tm256729-1_4seq1.xml","form_type":"4"}},{"id":1267468,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-14T21:55:57.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":10,"price":56.41,"value":564.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":4803,"source":{"system":"sec-edgar","filing":"0001104659-25-014257","document":"tm256729-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925014257/tm256729-1_4seq1.xml","form_type":"4"}},{"id":1267467,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-14T21:55:57.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":600,"price":56.39,"value":33834.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":4813,"source":{"system":"sec-edgar","filing":"0001104659-25-014257","document":"tm256729-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925014257/tm256729-1_4seq1.xml","form_type":"4"}},{"id":1274102,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":false,"shares":2031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2031},"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274101,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-09","kind":"exercise","planned":true,"acquired":false,"shares":4189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":21601,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":4189},"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274100,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-09","kind":"exercise","planned":true,"acquired":false,"shares":3437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."}],"balance_after":3437,"derivative":{"underlying":"Common Stock","underlying_shares":3437},"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274099,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":4,"price":57.5,"value":230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":5413,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274098,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-11","kind":"sale","planned":true,"acquired":false,"shares":1023,"price":57.51,"value":58832.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":5417,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274097,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-11","kind":"exercise","planned":true,"acquired":true,"shares":2031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":6440,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274096,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":2295,"price":59.3408,"value":136187.136,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $59.1400 to $59.3600 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":4409,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274095,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":1894,"price":58.3928,"value":110595.9632,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.0750 to $58.8900 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":6704,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274094,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-09","kind":"exercise","planned":true,"acquired":true,"shares":4189,"price":6.8,"value":28485.2,"ownership":{"direct":true},"balance_after":8598,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1274093,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-12T02:46:12.000Z","date":"2025-02-09","kind":"exercise","planned":true,"acquired":true,"shares":3437,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":4409,"source":{"system":"sec-edgar","filing":"0001104659-25-011677","document":"tm256299-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925011677/tm256299-3_4seq1.xml","form_type":"4"}},{"id":1278829,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-07T22:05:53.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":200,"price":61.95,"value":12390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."}],"balance_after":972,"source":{"system":"sec-edgar","filing":"0001104659-25-010610","document":"tm255903-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925010610/tm255903-1_4seq1.xml","form_type":"4"}},{"id":1278828,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-07T22:05:53.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":1133,"price":61.0147,"value":69129.6551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $60.67 to $61.49. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1172,"source":{"system":"sec-edgar","filing":"0001104659-25-010610","document":"tm255903-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925010610/tm255903-1_4seq1.xml","form_type":"4"}},{"id":1278827,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-07T22:05:53.000Z","date":"2025-02-05","kind":"sale","planned":true,"acquired":false,"shares":1733,"price":60.0811,"value":104120.5463,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $59.54 to $60.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2305,"source":{"system":"sec-edgar","filing":"0001104659-25-010610","document":"tm255903-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925010610/tm255903-1_4seq1.xml","form_type":"4"}},{"id":1285015,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2025-02-05T02:23:52.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":4513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":9024,"derivative":{"underlying":"Common Stock","underlying_shares":4513},"source":{"system":"sec-edgar","filing":"0001104659-25-009284","document":"tm255457-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925009284/tm255457-2_4seq1.xml","form_type":"4"}},{"id":1285014,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-05T02:23:52.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":1447,"price":59.43,"value":85995.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":4038,"source":{"system":"sec-edgar","filing":"0001104659-25-009284","document":"tm255457-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925009284/tm255457-2_4seq1.xml","form_type":"4"}},{"id":1285013,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2025-02-05T02:23:52.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":4513,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":5485,"source":{"system":"sec-edgar","filing":"0001104659-25-009284","document":"tm255457-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465925009284/tm255457-2_4seq1.xml","form_type":"4"}},{"id":1366676,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":11642,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":37108,"derivative":{"exercise_price":30.66,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":11642},"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366675,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":28717,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock options were granted on November 9, 2020. The options are fully vested."}],"balance_after":71283,"derivative":{"exercise_price":24.29,"expiration_date":"2030-11-09","underlying":"Common Stock","underlying_shares":28717},"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366674,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":false,"shares":20622,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":25790,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":20622},"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366673,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":200,"price":68.43,"value":13686.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."}],"balance_after":972,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366672,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":11070,"price":67.5585,"value":747872.595,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $67.33 to $68.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1172,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366671,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":17540,"price":66.9484,"value":1174274.936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $66.33 to $67.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12242,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366670,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"sale","planned":true,"acquired":false,"shares":38051,"price":65.6763,"value":2499048.8913,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.18 to $66.1799 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":29782,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366669,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":11642,"price":30.66,"value":356943.72,"ownership":{"direct":true},"balance_after":67833,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366668,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":28717,"price":24.29,"value":697535.93,"ownership":{"direct":true},"balance_after":56191,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1366667,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-11-14T02:04:32.000Z","date":"2024-11-11","kind":"exercise","planned":true,"acquired":true,"shares":20622,"price":6.8,"value":140229.6,"ownership":{"direct":true},"balance_after":27474,"source":{"system":"sec-edgar","filing":"0001104659-24-117942","document":"tm2428383-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924117942/tm2428383-1_4seq1.xml","form_type":"4"}},{"id":1563515,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-03-22T20:16:08.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":9066,"price":39.33,"value":356565.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $38.75 to $39.72. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6852,"source":{"system":"sec-edgar","filing":"0001104659-24-037880","document":"tm249484-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924037880/tm249484-1_4seq1.xml","form_type":"4"}},{"id":1563514,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-03-22T20:16:08.000Z","date":"2024-03-20","kind":"sale","planned":false,"acquired":false,"shares":9169,"price":38.22,"value":350439.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $37.75 to $38.68. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15918,"source":{"system":"sec-edgar","filing":"0001104659-24-037880","document":"tm249484-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924037880/tm249484-1_4seq1.xml","form_type":"4"}},{"id":1569057,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-03-20T00:52:17.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":15515,"price":39.22,"value":608498.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.07 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":25087,"source":{"system":"sec-edgar","filing":"0001104659-24-036312","document":"tm249308-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924036312/tm249308-2_4seq1.xml","form_type":"4"}},{"id":1629512,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-22T00:00:42.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":67000,"derivative":{"exercise_price":49.23,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001104659-24-026154","document":"tm246920-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924026154/tm246920-1_4seq1.xml","form_type":"4"}},{"id":1629511,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2024-02-22T00:00:42.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."}],"balance_after":22000,"derivative":{"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001104659-24-026154","document":"tm246920-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924026154/tm246920-1_4seq1.xml","form_type":"4"}},{"id":1629510,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-22T00:00:42.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":33750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied."}],"balance_after":40602,"source":{"system":"sec-edgar","filing":"0001104659-24-026154","document":"tm246920-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924026154/tm246920-1_4seq1.xml","form_type":"4"}},{"id":1646407,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2024-02-14T01:47:39.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":false,"shares":2031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."}],"balance_after":2031,"derivative":{"underlying":"Common Stock","underlying_shares":2031},"source":{"system":"sec-edgar","filing":"0001104659-24-022538","document":"tm246165-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924022538/tm246165-3_4seq1.xml","form_type":"4"}},{"id":1646406,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2024-02-14T01:47:39.000Z","date":"2024-02-09","kind":"exercise","planned":false,"acquired":false,"shares":3438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."}],"balance_after":6874,"derivative":{"underlying":"Common Stock","underlying_shares":3438},"source":{"system":"sec-edgar","filing":"0001104659-24-022538","document":"tm246165-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924022538/tm246165-3_4seq1.xml","form_type":"4"}},{"id":1646405,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-14T01:47:39.000Z","date":"2024-02-13","kind":"sale","planned":false,"acquired":false,"shares":615,"price":49.83,"value":30645.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":6852,"source":{"system":"sec-edgar","filing":"0001104659-24-022538","document":"tm246165-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924022538/tm246165-3_4seq1.xml","form_type":"4"}},{"id":1646404,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-14T01:47:39.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":1023,"price":51.38,"value":52561.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":7467,"source":{"system":"sec-edgar","filing":"0001104659-24-022538","document":"tm246165-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924022538/tm246165-3_4seq1.xml","form_type":"4"}},{"id":1646403,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-14T01:47:39.000Z","date":"2024-02-11","kind":"exercise","planned":false,"acquired":true,"shares":2031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":8490,"source":{"system":"sec-edgar","filing":"0001104659-24-022538","document":"tm246165-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924022538/tm246165-3_4seq1.xml","form_type":"4"}},{"id":1646402,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-14T01:47:39.000Z","date":"2024-02-09","kind":"exercise","planned":false,"acquired":true,"shares":3438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":6459,"source":{"system":"sec-edgar","filing":"0001104659-24-022538","document":"tm246165-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924022538/tm246165-3_4seq1.xml","form_type":"4"}},{"id":1659067,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T23:55:36.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":4513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":13537,"derivative":{"underlying":"Common Stock","underlying_shares":4513},"source":{"system":"sec-edgar","filing":"0001104659-24-010800","document":"tm245251-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924010800/tm245251-5_4seq1.xml","form_type":"4"}},{"id":1659066,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-05T23:55:36.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":1492,"price":45.06,"value":67229.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":3021,"source":{"system":"sec-edgar","filing":"0001104659-24-010800","document":"tm245251-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924010800/tm245251-5_4seq1.xml","form_type":"4"}},{"id":1659065,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2024-02-05T23:55:36.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":4513,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":4513,"source":{"system":"sec-edgar","filing":"0001104659-24-010800","document":"tm245251-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465924010800/tm245251-5_4seq1.xml","form_type":"4"}},{"id":1739192,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-16T21:05:28.000Z","date":"2023-11-14","kind":"exercise","planned":true,"acquired":false,"shares":12030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":46412,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":12030},"source":{"system":"sec-edgar","filing":"0001104659-23-119095","document":"tm2330902-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923119095/tm2330902-2_4seq1.xml","form_type":"4"}},{"id":1739191,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-16T21:05:28.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":13677,"price":32.0113,"value":437818.5501,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $32.00 to $32.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-119095","document":"tm2330902-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923119095/tm2330902-2_4seq1.xml","form_type":"4"}},{"id":1739190,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-16T21:05:28.000Z","date":"2023-11-14","kind":"exercise","planned":true,"acquired":true,"shares":12030,"price":6.8,"value":81804.0,"ownership":{"direct":true},"balance_after":13677,"source":{"system":"sec-edgar","filing":"0001104659-23-119095","document":"tm2330902-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923119095/tm2330902-2_4seq1.xml","form_type":"4"}},{"id":1744089,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-09","kind":"exercise","planned":true,"acquired":false,"shares":3438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":58442,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":3438},"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744088,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-08","kind":"exercise","planned":true,"acquired":false,"shares":5712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":61880,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":5712},"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744087,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-09","kind":"sale","planned":true,"acquired":false,"shares":1719,"price":28,"value":48132.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."}],"balance_after":1647,"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744086,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-09","kind":"sale","planned":true,"acquired":false,"shares":1719,"price":27.3712,"value":47051.0928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $26.86 to $27.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3366,"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744085,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-09","kind":"exercise","planned":true,"acquired":true,"shares":3438,"price":6.8,"value":23378.4,"ownership":{"direct":true},"balance_after":5085,"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744084,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-08","kind":"sale","planned":true,"acquired":false,"shares":2233,"price":29.3129,"value":65455.7057,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.04 to $29.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1647,"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744083,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-08","kind":"sale","planned":true,"acquired":false,"shares":3479,"price":28.6429,"value":99648.6491,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.04 to $29.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":3880,"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1744082,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-13T22:44:01.000Z","date":"2023-11-08","kind":"exercise","planned":true,"acquired":true,"shares":5712,"price":6.8,"value":38841.6,"ownership":{"direct":true},"balance_after":7359,"source":{"system":"sec-edgar","filing":"0001104659-23-117365","document":"tm2330582-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923117365/tm2330582-1_4seq1.xml","form_type":"4"}},{"id":1747703,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-07T23:17:13.000Z","date":"2023-11-03","kind":"exercise","planned":true,"acquired":false,"shares":80,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":67592,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":80},"source":{"system":"sec-edgar","filing":"0001104659-23-115368","document":"tm2330154-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923115368/tm2330154-1_4seq1.xml","form_type":"4"}},{"id":1747702,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-07T23:17:13.000Z","date":"2023-11-03","kind":"sale","planned":true,"acquired":false,"shares":80,"price":28,"value":2240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."}],"balance_after":1647,"source":{"system":"sec-edgar","filing":"0001104659-23-115368","document":"tm2330154-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923115368/tm2330154-1_4seq1.xml","form_type":"4"}},{"id":1747701,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-11-07T23:17:13.000Z","date":"2023-11-03","kind":"exercise","planned":true,"acquired":true,"shares":80,"price":6.8,"value":544.0,"ownership":{"direct":true},"balance_after":1727,"source":{"system":"sec-edgar","filing":"0001104659-23-115368","document":"tm2330154-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923115368/tm2330154-1_4seq1.xml","form_type":"4"}},{"id":1785922,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-07T21:48:27.000Z","date":"2023-09-05","kind":"exercise","planned":true,"acquired":false,"shares":4519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":67672,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":4519},"source":{"system":"sec-edgar","filing":"0001104659-23-099017","document":"tm2325695-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923099017/tm2325695-1_4seq1.xml","form_type":"4"}},{"id":1785921,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-09-07T21:48:27.000Z","date":"2023-09-05","kind":"sale","planned":true,"acquired":false,"shares":6166,"price":28.0502,"value":172957.5332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $28.00 to $28.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":1647,"source":{"system":"sec-edgar","filing":"0001104659-23-099017","document":"tm2325695-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923099017/tm2325695-1_4seq1.xml","form_type":"4"}},{"id":1785920,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-09-07T21:48:27.000Z","date":"2023-09-05","kind":"exercise","planned":true,"acquired":true,"shares":4519,"price":6.8,"value":30729.2,"ownership":{"direct":true},"balance_after":7813,"source":{"system":"sec-edgar","filing":"0001104659-23-099017","document":"tm2325695-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923099017/tm2325695-1_4seq1.xml","form_type":"4"}},{"id":1812085,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-09T20:30:20.000Z","date":"2023-08-09","kind":"exercise","planned":true,"acquired":false,"shares":1718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":72191,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":1718},"source":{"system":"sec-edgar","filing":"0001104659-23-089331","document":"tm2323302-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923089331/tm2323302-1_4seq1.xml","form_type":"4"}},{"id":1812084,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-09T20:30:20.000Z","date":"2023-08-07","kind":"exercise","planned":true,"acquired":false,"shares":8591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":73909,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":8591},"source":{"system":"sec-edgar","filing":"0001104659-23-089331","document":"tm2323302-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923089331/tm2323302-1_4seq1.xml","form_type":"4"}},{"id":1812083,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-08-09T20:30:20.000Z","date":"2023-08-09","kind":"sale","planned":true,"acquired":false,"shares":1718,"price":24.66,"value":42365.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."}],"balance_after":3294,"source":{"system":"sec-edgar","filing":"0001104659-23-089331","document":"tm2323302-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923089331/tm2323302-1_4seq1.xml","form_type":"4"}},{"id":1812082,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-08-09T20:30:20.000Z","date":"2023-08-09","kind":"exercise","planned":true,"acquired":true,"shares":1718,"price":6.8,"value":11682.4,"ownership":{"direct":true},"balance_after":5012,"source":{"system":"sec-edgar","filing":"0001104659-23-089331","document":"tm2323302-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923089331/tm2323302-1_4seq1.xml","form_type":"4"}},{"id":1812081,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-08-09T20:30:20.000Z","date":"2023-08-07","kind":"sale","planned":true,"acquired":false,"shares":11223,"price":24.1778,"value":271347.4494,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023."}],"balance_after":3294,"source":{"system":"sec-edgar","filing":"0001104659-23-089331","document":"tm2323302-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923089331/tm2323302-1_4seq1.xml","form_type":"4"}},{"id":1812080,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Lee Jennifer Kayden","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-08-09T20:30:20.000Z","date":"2023-08-07","kind":"exercise","planned":true,"acquired":true,"shares":8591,"price":6.8,"value":58418.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 986 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2023."}],"balance_after":14517,"source":{"system":"sec-edgar","filing":"0001104659-23-089331","document":"tm2323302-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923089331/tm2323302-1_4seq1.xml","form_type":"4"}},{"id":2016674,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2023-02-15T01:59:28.000Z","date":"2023-02-11","kind":"exercise","acquired":false,"shares":2031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."}],"balance_after":4062,"derivative":{"underlying":"Common Stock","underlying_shares":2031},"source":{"system":"sec-edgar","filing":"0001104659-23-022113","document":"tm236871-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923022113/tm236871-9_4seq1.xml","form_type":"4"}},{"id":2016673,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-02-15T01:59:28.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":635,"price":26.87,"value":17062.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":4940,"source":{"system":"sec-edgar","filing":"0001104659-23-022113","document":"tm236871-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923022113/tm236871-9_4seq1.xml","form_type":"4"}},{"id":2016672,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-02-15T01:59:28.000Z","date":"2023-02-11","kind":"exercise","acquired":true,"shares":2031,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":5575,"source":{"system":"sec-edgar","filing":"0001104659-23-022113","document":"tm236871-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923022113/tm236871-9_4seq1.xml","form_type":"4"}},{"id":2016671,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-02-15T00:19:04.000Z","date":"2023-02-09","kind":"sale","acquired":false,"shares":1204,"price":27.51,"value":33122.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":3544,"source":{"system":"sec-edgar","filing":"0001104659-23-022065","document":"tm236871-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923022065/tm236871-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-02-13"}},{"id":2020145,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2023-02-13T22:04:32.000Z","date":"2023-02-09","kind":"exercise","acquired":false,"shares":3438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."}],"balance_after":10312,"derivative":{"underlying":"Common Stock","underlying_shares":3438},"source":{"system":"sec-edgar","filing":"0001104659-23-019835","document":"tm236605-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923019835/tm236605-6_4seq1.xml","form_type":"4"}},{"id":2020144,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-02-13T22:04:32.000Z","date":"2023-02-09","kind":"sale","acquired":false,"shares":1192,"price":27.66,"value":32970.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":3556,"source":{"system":"sec-edgar","filing":"0001104659-23-019835","document":"tm236605-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923019835/tm236605-6_4seq1.xml","form_type":"4"}},{"id":2020143,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2023-02-13T22:04:32.000Z","date":"2023-02-09","kind":"exercise","acquired":true,"shares":3438,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":4748,"source":{"system":"sec-edgar","filing":"0001104659-23-019835","document":"tm236605-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923019835/tm236605-6_4seq1.xml","form_type":"4"}},{"id":2033193,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T21:06:30.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":46900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":46900,"derivative":{"exercise_price":27.35,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":46900},"source":{"system":"sec-edgar","filing":"0001104659-23-010483","document":"tm235340-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923010483/tm235340-1_4seq1.xml","form_type":"4"}},{"id":2033192,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T21:06:30.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":18050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":18050,"derivative":{"underlying":"Common Stock","underlying_shares":18050},"source":{"system":"sec-edgar","filing":"0001104659-23-010483","document":"tm235340-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465923010483/tm235340-1_4seq1.xml","form_type":"4"}},{"id":2394680,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2022-02-16T00:28:51.000Z","date":"2022-02-11","kind":"exercise","acquired":false,"shares":2032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date."}],"balance_after":6093,"derivative":{"underlying":"Common Stock","underlying_shares":2032},"source":{"system":"sec-edgar","filing":"0001104659-22-023948","document":"tm226880-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465922023948/tm226880-1_4seq1.xml","form_type":"4"}},{"id":2394679,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2022-02-16T00:28:51.000Z","date":"2022-02-15","kind":"sale","acquired":false,"shares":722,"price":6.1,"value":4404.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units."}],"balance_after":1310,"source":{"system":"sec-edgar","filing":"0001104659-22-023948","document":"tm226880-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465922023948/tm226880-1_4seq1.xml","form_type":"4"}},{"id":2394678,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Common Stock","published_at":"2022-02-16T00:28:51.000Z","date":"2022-02-11","kind":"exercise","acquired":true,"shares":2032,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":2032,"source":{"system":"sec-edgar","filing":"0001104659-22-023948","document":"tm226880-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465922023948/tm226880-1_4seq1.xml","form_type":"4"}},{"id":2401907,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-12T02:31:23.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":82500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":82500,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":82500},"source":{"system":"sec-edgar","filing":"0001104659-22-020887","document":"tm226394-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465922020887/tm226394-1_4seq1.xml","form_type":"4"}},{"id":2401906,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":23364,"kind":"person","name":"Lee Jennifer Kayden","position":1,"cik":"0001801372","reported_name":"Chien Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Head of North America"}}],"security":"Restricted Stock Units","published_at":"2022-02-12T02:31:23.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date."}],"balance_after":13750,"derivative":{"underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001104659-22-020887","document":"tm226394-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1801372/000110465922020887/tm226394-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2022-02-12T02:31:23.000000Z,2401906"}